Search: onr:"swepub:oai:DiVA.org:uu-336233" >
Drugs for metabolic...
Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.
-
- Bosco, Cecilia (author)
- Kings Coll London, Sch Canc & Pharmaceut Sci Translat Oncol & Urol R, London, England
-
- Wong, Chloe (author)
- Kings Coll London, Sch Canc & Pharmaceut Sci Translat Oncol & Urol R, London, England
-
- Garmo, Hans (author)
- Kings Coll London, Sch Canc & Pharmaceut Sci Translat Oncol & Urol R, London, England.; Uppsala Univ, Reg Canc Ctr, Uppsala, Sweden.
-
show more...
-
- Crawley, Danielle (author)
- Kings Coll London, Sch Canc & Pharmaceut Sci Translat Oncol & Urol R, London, England
-
- Holmberg, Lars (author)
- Uppsala universitet,Endokrinkirurgi,Kings Coll London, Sch Canc & Pharmaceut Sci Translat Oncol & Urol R, London, England
-
- Hammar, Niklas (author)
- Karolinska Institutet
-
- Adolfsson, Jan (author)
- Karolinska Institutet
-
- Stattin, Pär (author)
- Uppsala universitet,Urologkirurgi
-
- Van Hemelrijck, Mieke (author)
- Kings Coll London, Sch Canc & Pharmaceut Sci Translat Oncol & Urol R, London, England
-
show less...
-
Kings Coll London, Sch Canc & Pharmaceut Sci Translat Oncol & Urol R, London, England Kings Coll London, Sch Canc & Pharmaceut Sci Translat Oncol & Urol R, London, England; Uppsala Univ, Reg Canc Ctr, Uppsala, Sweden. (creator_code:org_t)
- 2017-10-17
- 2018
- English.
-
In: BJU International. - : Wiley. - 1464-4096 .- 1464-410X. ; 121:2, s. 260-267
- Related links:
-
https://kclpure.kcl....
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- OBJECTIVE: To evaluate whether drugs for metabolic conditions influence prostate cancer-specific mortality in men starting gonadotrophin-releasing hormone (GnRH) agonists, as it is unclear whether metabolic syndrome and its related drugs is affecting treatment response in men with prostate cancer on GnRH agonists.PATIENTS AND METHODS: We selected all men receiving GnRH agonists as primary treatment in the Prostate Cancer data Base Sweden (PCBaSe) (n = 9267). Use of drugs for metabolic conditions (i.e. anti-diabetes, anti-dyslipidaemia, and antihypertension) in relation to all-cause, cardiovascular disease (CVD), and prostate cancer-specific death were studied using multivariate Cox proportional hazard and Fine and Gray competing regression models.RESULTS: In all, 6322 (68%) men used at least one drug for a metabolic condition at GnRH agonist initiation: 46% on antihypertensive drugs only, 32% on drugs for dyslipidaemia and hypertension, and ~10% on drugs for more than two metabolic conditions. Cox models indicated a weak increased risk of prostate cancer death in men who were on drugs for hypertension only (hazard ratio [HR] 1.12, 95% confidence interval [CI] 1.03-1.23) or drugs for hyperglycaemia (HR 1.19, 95% CI 1.06-1.35) at GnRH agonist initiation. However, upon taking into account competing risk from CVD death, none of the drugs for metabolic conditions were associated with an increased risk of prostate cancer death.CONCLUSION: We did not find evidence for a better or worse response to GnRH agonists in men with prostate cancer who were also on drugs for hypertension, dyslipidaemia, or hyperglycaemia.
Keyword
- #PCSM
- #ProstateCancer
- GnRH agonist
- dyslipidaemia
- hyperglycaemia
- hypertension
- metabolic syndrome
- prostate cancer death
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database